Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case postmarketing surveillance study
No new safety concerns were identified during this 3-year postmarketing surveillance study of baricitinib in Japanese patients with RA. Patients and clinicians should be cognizant of herpes zoster and other serious infection risks during baricitinib treatment, especially in the first 6 months.
Authors
- Atsushi Nishikawa (ORCID: https://orcid.org/0000-0003-4325-1160)
- Nobunori Takahashi (ORCID: https://orcid.org/0000-0001-6937-3567)
- Michiaki Takagi (ORCID: https://orcid.org/0000-0002-3052-787X)
- Nami Okamoto (ORCID: https://orcid.org/0000-0002-9085-5250)
- Yoshiya Tanaka (ORCID: https://orcid.org/0000-0002-0807-7139)
- Naoto Tamura (ORCID: https://orcid.org/0000-0003-1729-2954)
- Hiroaki Matsuno (ORCID: https://orcid.org/0000-0002-2195-5717)
- Machiko Minatoya (ORCID: https://orcid.org/0000-0002-1306-3073)
- Masataka Kuwana (ORCID: https://orcid.org/0000-0001-8352-6136)
- Naoto Tsujimoto
- Tatsuya Atsumi (ORCID: https://orcid.org/0000-0001-5657-962X)
- Tsutomu Takeuchi (ORCID: https://orcid.org/0000-0003-1111-8218)
- Atsuo Nakajima
- Ayako Nakajima (ORCID: https://orcid.org/0000-0002-6789-1739)
- Takao Fujii
- Taeko Ishii
Institutions
- Yamagata University (JP)
- Aichi Medical University (JP)
- University of Occupational and Environmental Health Japan (JP)
- Wakayama Medical University (JP)
- Keio University (JP)
- Hokkaido University (JP)
- Juntendo University (JP)
- Eli Lilly (Japan) (JP)
- Osaka Rosai Hospital (JP)
- Japanese Society for Dialysis Therapy (JP)
- Institute for Rheumatic Diseases (Japan) (JP)
- Mie University Hospital (JP)
- Nippon Medical School (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Modern Rheumatology
- Published
- 2024-08-09
- DOI
- https://doi.org/10.1093/mr/roae064
- Citations
- 9
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 4.23